HIMS
T14.0% portfolioHims & Hers Health, Inc.
Archetypes '25: Trad WivesArchetypes '26: OptimizersBeauty '26: HaircareGLP-1 Long '24: GLP1 Equip/DistribGLP-1 Long '24: Peptide Producers/DesignersHaveNots Shorts '25: Premium SubscriptionsLooksmaxxing '26: Skin Care & Body TreatmentRetail Shopping '25: Single-Vertical EcomSmall Themes '24: Value-Based Care
OverviewHims & Hers Health, Inc. is a digital platform connecting consumers with medical professionals for personalized health solutions. It offers prescriptions for va
Hims & Hers Health, Inc. is a digital platform connecting consumers with medical professionals for personalized health solutions. It offers prescriptions for various needs, including sexual health, skincare, hair care, weight loss (branded GLP-1s), testosterone, and menopause. Serving nearly 2.6 million subscribers, the company completed its global expansion via Eucalyptus and is advancing peptide offerings, leveraging AI.
- What They Do (Plain English & Analogies)
- Hims & Hers Health, Inc. operates like a digital health hub or a 'Netflix for healthcare.' It connects people directly with doctors online for virtual appointments and ongoing care, and then delivers a wide range of health and wellness products straight to their homes. This includes prescription medications, over-the-counter drugs, devices, cosmetics, and supplements. They focus on areas like general wellness, sexual health, skincare, hair care, weight loss, and hormone therapies. Imagine a convenient, personalized digital clinic, pharmacy, and lab all in one app, where you can get treatments, refills, and even at-home tests, all designed to help you feel your best every day.
- Very Brief History
- Founded in 2017, Hims initially focused on men's health products like those for erectile dysfunction and hair loss. It quickly expanded to include a women's brand, Hers, and diversified into dermatology, sexual health, and weight management. After going public via SPAC in 2021, the company shifted towards vertical integration, building its own compounding pharmacies and lab operations. Recent acquisitions include YourBio for at-home blood sampling technology in Q1 2026, and the planned acquisition of Eucalyptus in the second half of 2026 to expand its international footprint. The company has also accelerated its focus on GLP-1s for weight loss, whole-body labs, and hormone therapies.
- "Street Stereotype"
- On the Street, HIMS is often seen as a digital subscription health play that initially appeared to be a marketing-led 'Instagram of pharmacies.' However, it is now recasting itself as a vertically integrated telehealth platform. Investors are divided, with some viewing it as a high-growth, platform-driven healthcare disruptor, while others perceive it as a GLP-1/compounding-dependent story facing regulatory and margin risks.
- Subsidiaries On Linked In*
- Hims & Hers — Parent company and consumer brands; LinkedIn: hims-hers-health
- Zava — Europe telehealth, acquired; LinkedIn: zava-health
- Livewell — Canada telehealth, acquired; LinkedIn: livewell-health
- YourBio Health — At-home microneedle blood sampling technology, acquired/closed Q1 2026; LinkedIn: yourbio-health
- Eucalyptus — Signed to be acquired in 2H 2026, expands U.K./Australia/Japan footprint; LinkedIn: eucalyptus-health
- Apostrophe — Dermatology acquisition; LinkedIn: apostrophe-skin
- Customer Sectors & Example Clients
- Hims & Hers primarily serves individual consumers (direct-to-consumer subscribers) across various health and wellness needs, including general wellness, sexual health, dermatology, weight loss, hormone therapy, and preventive diagnostics. Secondary customers and partners include retail and wholesale partners for product distribution. Specific publicly referenced or logical partners include Novo Nordisk (for GLP-1 products like Wegovy), LillyDirect (for Zepbound and other Lilly products), and diagnostic technology partners like YourBio and historically, GRAIL. They also engage with pharma and biotech companies for innovative treatments and services.
- New Customers / Segments They'Re Targeting
- Hims & Hers is aggressively targeting new customer segments by expanding into proactive and preventative care offerings. This includes newer specialties like testosterone support for men, menopause solutions for women, and comprehensive lab testing for deeper health insights. They are also focusing on a globally unified approach to weight loss, aiming to serve a broader audience with a wider assortment of innovative medications. The company is preparing to enter emerging categories like peptide therapies, focusing on a physician-first, transparent, and clinically rigorous approach. Geographically, they are expanding their reach internationally, with a planned acquisition of Eucalyptus to extend leadership across Australia, the U.K., Germany, Japan, and Canada.
- Supply Chain And Sourcing Geographies
- Hims & Hers operates a verticalized supply chain, which includes its own compounding pharmacies and lab operations, spanning over 1 million square feet of infrastructure. This allows for individualized dosing and formulations, improved cost efficiencies, and direct control over the process. The company has also invested in its own U.S.-based peptide manufacturing facility, acquired last year, to control API manufacturing domestically, ensuring quality, purity, reliability, and brand trust for future peptide therapies. They leverage their pharmacies to fulfill medications, including branded products like the Wegovy pill and pen from Novo Nordisk.
- Sales Geographies And Expansion Plans
- Hims & Hers currently sells its products primarily in the U.S.. The company has a growing international footprint, with existing operations in Europe through ZAVA and in Canada through Livewell. They have significant expansion plans, with the anticipated acquisition of Eucalyptus in the second half of 2026, which will extend their presence across Australia, the U.K., Germany, Japan, and Canada. The company aims to become the world's largest consumer health platform and a leading health and wellness service provider in each of its key markets globally.
- How Key Themes May Help/Hurt
- The buildout of the 'GLP-1 Long '24: Peptide Producers/Designers' theme is highly beneficial for Hims & Hers. As a company actively involved in offering GLP-1 solutions and preparing to enter the broader peptide therapy market, the rising prevalence of obesity globally (Bull1) directly increases the demand for their weight loss offerings and future peptide products. Hims & Hers' strategic pivot to prioritize branded GLP-1 products and its collaboration with Novo Nordisk aligns with the theme's Bull3, which highlights strategic partnerships enhancing distribution and innovation. Their investment in a U.S.-based peptide manufacturing facility positions them to capitalize on technological advancements in peptide synthesis (Bull2) by controlling quality and potentially improving cost efficiencies. However, the theme also presents potential challenges. Regulatory hurdles and approval processes (Bear2) remain a significant risk, as Hims & Hers is waiting for clearer FDA guidance on peptides. Potential side effects and long-term safety concerns of GLP-1 drugs (Bear3) could impact adoption rates, though Hims & Hers' focus on physician oversight and rigorous standards aims to mitigate this. The intensifying competitive landscape with new entrants (Bear1) could pressure margins and market share, especially as the GLP-1 and peptide markets evolve.
3 Main Long-Term Bull Details
- Verticalized, Multi-Specialty, and AI-Powered Platform: Hims & Hers is building a deeply integrated platform that owns its compounding, pharmacy, and lab operations, combined with advanced AI and data infrastructure. This creates a durable unit-economics advantage, enables personalized care at scale, and fosters a cross-sell flywheel as customers adopt multiple personalized solutions, leading to higher lifetime value and retention.
- Massive TAM Expansion and Rapid Specialty Rollouts: The company is aggressively expanding its total addressable market (TAM) by entering new, large categories like weight loss, labs, testosterone, and menopause, and has demonstrated the ability to quickly scale these new specialties. This repeatable go-to-market capability across underpenetrated categories, coupled with a focus on proactive and preventative care, positions them for sustained long-term growth.
- Aggressive International Expansion: Through strategic acquisitions like ZAVA, Livewell, and the pending Eucalyptus deal, Hims & Hers is rapidly expanding its global footprint. This international growth is expected to unlock significant incremental revenue, diversify revenue streams beyond the U.S., and create a multi-market, higher-powered revenue engine, with targets of hundreds of millions of people impacted and international break-even within 12-18 months post-Eucalyptus close.
3 Main Long-Term Bear Details
- Regulatory and Compounding Risk: The company faces ongoing regulatory risk, particularly concerning GLP-1 compounding and the evolving landscape for peptide therapies. Changes in FDA guidelines or the removal of compounding allowances could materially impact high-ticket revenue, complicate their weight loss offerings, and delay the launch or profitability of new categories.
- Near-term Margin Compression and Execution Risk from Investments: Hims & Hers is undergoing a period of heavy investment in technology, AI, new specialties, and international expansion. This can lead to near-term margin pressure and execution risk. If these growth investments fail to yield expected scale or if international integrations face challenges, profitability could deteriorate, and the path to long-term targets could be delayed.
- Competitive Pressure and Market Volatility: The telehealth and weight loss markets are highly competitive, with branded pharma companies launching their own direct-to-consumer channels (e.g., LillyDirect) and deep-pocketed incumbents. This intense competition, coupled with potential pricing pressure and the inherent volatility of new and evolving categories like GLP-1s and peptides, could compress HIMS's margins or market share if their differentiation is not strong enough.
- Competitors And Differentiation
- Hims & Hers competes with traditional healthcare providers, other telehealth platforms, and direct-to-consumer health brands. Their differentiation strategy centers on several key areas: **Global Scale and Vertical Integration:** They are rapidly becoming the world's largest consumer health platform, leveraging their own compounding, pharmacy, and lab infrastructure to offer personalized care at scale. This verticalization aims to create cost efficiencies and a high level of service. **Data and AI Infrastructure:** They are investing heavily in data and AI to build an agile platform that gets smarter with every customer interaction. This includes AI copilots for care coaches, Labs AI for explaining biomarker results, and an upcoming AI weight loss companion, all designed to personalize and enhance the customer and provider experience. **Broad Assortment and Proactive Care:** They offer a wide array of treatment options across numerous specialties, including newer areas like testosterone, menopause, and labs, moving beyond reactive treatment to proactive health management. **Strong Customer Relationships:** The platform is designed to foster long-term relationships by providing continuous, personalized care and support, aiming for higher engagement and retention. **Brand Trust and Quality:** They emphasize a physician-first, transparent, and clinically rigorous approach, particularly for emerging categories like peptides, backed by their domestic supply chain.
- Recent Performance & What The Market'S Focused On
- In Q1 2026, Hims & Hers reported revenue growth of 4% year-over-year to $608 million, with subscribers growing 9% year-over-year to nearly 2.6 million. Adjusted EBITDA was $44 million, representing a 7% adjusted EBITDA margin. The company incurred approximately $33 million in restructuring costs due to a strategic pivot in its weight loss business, shifting focus from compounded GLP-1 products to prioritizing branded products like Wegovy from Novo Nordisk. This pivot temporarily pressured U.S. revenue and adjusted EBITDA, but international growth remained strong, with revenue increasing nearly tenfold to $78 million. For Q2 2026, they anticipate revenue between $680 million and $700 million, and for the full year 2026, they raised their revenue outlook to $2.8 billion to $3 billion, with adjusted EBITDA expected between $275 million and $350 million. The market is focused on the success of the strategic pivot in weight loss, the acceleration of growth in new specialties like labs, testosterone, and menopause, and the progress of international expansion, particularly the integration of Eucalyptus. Investors are also closely watching the company's ability to achieve its ambitious 2030 targets of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA, while managing near-term margin compression from investments. The development of the peptide category and the role of AI in enhancing the customer experience are also key areas of market interest.
- Revenue Segments And Estimated Mix
- U.S. Operations — Mix: ~87% (Q1 2026); Source: Q1 2026 earnings transcript; Trend: Temporarily pressured by revenue recognition dynamics and weight loss pivot, but expected to accelerate.
- International Operations — Mix: ~13% (Q1 2026); Source: Q1 2026 earnings transcript; Trend: Increased nearly tenfold year-over-year in Q1 2026 to $78 million; strong growth driven by ZAVA and Livewell acquisitions.
- Product Brands
- Hims
- Hers
- Wegovy (via platform)
- Zepbound (via platform)
- Juniper (market-specific women/weight brand)
- Zava (Europe telehealth)
- Livewell (Canada telehealth)
- Apostrophe (dermatology)
- YourBio (at-home blood testing technology)
Bull / Bear DetailsHims & Hers is rapidly evolving into a global, consumer-centric health ecosystem, accelerating growth through a strategic pivot to branded GLP-1s, robust intern
Thesis
Hims & Hers is rapidly evolving into a global, consumer-centric health ecosystem, accelerating growth through a strategic pivot to branded GLP-1s, robust international expansion, and scaling new specialties like labs and hormone therapies. Significant investments in AI and verticalized infrastructure are building a defensible platform for personalized, proactive care, including future peptide offerings. Despite near-term margin compression, the company remains confident in its ambitious 2030 targets. (Updated: 2026-07-27)
Bull case
Hims & Hers is demonstrating robust international expansion, with Q1 2026 international revenue growing nearly tenfold to $78 million. The planned acquisition of Eucalyptus in 2H 2026 will further extend its global leadership across key markets, including Australia, the U.K., Germany, Japan, and Canada, significantly broadening its addressable market and creating a multi-market revenue engine for durable growth.
The company's proactive care strategy is gaining traction, with strong momentum in new specialties like testosterone, menopause, and labs. The acquisition of YourBio enhances at-home diagnostic capabilities, enabling deeper health insights and personalized treatment plans. This approach fosters longer-term customer relationships, as evidenced by 95% of Hims testosterone customers seeing increased levels within two months, driving higher retention and lifetime value.
Hims & Hers is building a formidable structural advantage through its advanced technology and AI infrastructure. With a growing AI team and tools like Labs AI and an AI copilot for providers, the platform delivers personalized, efficient care. This closed-loop proprietary data flywheel, combined with modular architecture, enables faster product expansion, deeper customer engagement, and a unique, hard-to-replicate competitive moat.
Bear case
Hims & Hers faces continued near-term margin compression and execution risk from heavy investments and strategic shifts. Q1 2026 saw a 7% adjusted EBITDA margin and 65% GAAP gross margin, impacted by $33 million in restructuring costs related to its compounded GLP-1 supply chain. Gross margins are expected to compress further by a couple of points in coming quarters as the company prioritizes scaling lower-margin weight loss, labs, and international markets.
While the strategic pivot to branded GLP-1s mitigates compounding regulatory risk, the transition incurred $33 million in restructuring costs and may introduce new competitive pressures from branded pharma's direct-to-consumer channels. The long-term profitability profile of branded GLP-1 distribution, especially with potential future price competition and the need to maintain high subscriber acquisition rates, remains a key uncertainty.
International expansion, while a key growth driver, presents material risks including integration challenges and potential near-term margin drag. The Eucalyptus acquisition, expected to close in 2H 2026, requires a significant upfront payment of approximately $240 million and ongoing investments, contributing to expected gross margin compression as new international markets are scaled. Achieving profitability in these new regions within projected timelines remains an execution challenge.
Bull / Bear Case
- Bear Case
- Hims & Hers faces significant near-term margin compression and execution risk due to heavy investments and strategic shifts. Q1 2026 saw a low 7% adjusted EBITDA margin and 65% GAAP gross margin, impacted by $33 million in restructuring costs related to its compounded GLP-1 supply chain pivot. Gross margins are expected to compress further as the company prioritizes scaling lower-margin weight loss, labs, and international markets. The company reported a GAAP net loss of $92 million in Q1 2026 and does not expect to return to net income profitability until 2027. The long-term profitability of branded GLP-1 distribution remains uncertain amid potential price competition, and recent mixed signals regarding FDA's stance on peptides introduce regulatory uncertainty and potential delays in a key growth area. International expansion, while a growth driver, carries integration challenges and significant upfront investment, contributing to near-term margin drag.
- Bull Case
- Hims & Hers is poised for accelerating growth in 2026, driven by a strategic pivot to branded GLP-1s, which is rapidly adding over 100,000 new weight loss subscribers monthly. The company is also seeing strong momentum in new specialties such as testosterone, menopause, and labs. Its robust international expansion, evidenced by a nearly tenfold increase in Q1 2026 international revenue and the completed acquisition of Eucalyptus, significantly broadens its global addressable market. Furthermore, Hims & Hers is building a formidable competitive moat through substantial investments in AI and verticalized infrastructure, including a U.S.-based peptide manufacturing facility. This technological advantage enables personalized, proactive care and faster product expansion. The potential easing of FDA restrictions on peptides could unlock a multi-billion dollar market, where Hims & Hers is strategically positioned to be a leader, reinforcing confidence in its ambitious 2030 targets of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA.
- More Compelling & Why
- Bear. The stock's EV/EBITDA ratio of 183.19 is exceptionally high, significantly above the industry median, indicating a valuation that prices in substantial future growth and profitability not yet realized. The strongest argument for the bear case is the continued near-term margin compression and GAAP net losses, coupled with significant execution risks from heavy investments in new, lower-margin specialties and international expansion. My view would flip to bullish if the company demonstrates a clear and sustained path to GAAP net income profitability and significantly improves its adjusted EBITDA margins, justifying its premium valuation.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| Eucalyptus Acquisition Closing | The closing of this acquisition is crucial for Hims & Hers' international expansion strategy, significantly broadening its global footprint across Australia, the U.K., Germany, Japan, and Canada, and contributing to its long-term revenue targets. | Official announcement of Eucalyptus acquisition closing in the second half of 2026. Details on the integration timeline and initial financial contributions. | Bullish: Acquisition closes as planned in 2H 2026, enabling further international scale and market leadership. | Company press releases, SEC filings (8-K), next earnings call (Q2 2026 on August 10, 2026). | News aggregators for M&A announcements related to Hims & Hers or Eucalyptus. | |
| Peptide Therapy Regulatory Clarity & Launch Readiness | Regulatory clarity from the FDA regarding peptide therapies is a critical precursor for Hims & Hers to safely and effectively enter this 'extremely large' emerging category, leveraging its verticalized supply chain and physician oversight to become a market leader. | FDA announcements or guidance updates on peptide therapies, specifically in July 2026 and end of year 2026. Company announcements regarding its readiness to launch peptide offerings, focusing on physician insights, oversight, and high-quality treatments. | Bullish: FDA provides clear regulatory path in July 2026. Hims & Hers announces a timeline for launching peptide therapies with its 'best in market' approach. | FDA official announcements (FDA.gov), company press releases, earnings calls (Q2 2026 on August 10, 2026). | FDA.gov: News releases, guidance documents related to peptide therapies. Industry news sites covering peptide regulation. | AlphaSense/Bloomberg Terminal: Regulatory news feeds for FDA. |
| International Revenue Growth & Path to Break-even (excluding Eucalyptus initial impact) | Strong international revenue growth, driven by existing acquisitions (ZAVA, Livewell) and organic expansion, is vital for Hims & Hers to achieve its global scale ambitions and demonstrate the viability of its model beyond the U.S., paving the way for future profitability in these markets. | International revenue contribution in Q2 2026 and subsequent quarters (Q1 2026 was $78M, nearly tenfold year-over-year growth). Progress towards international segment profitability and break-even. | Bullish: Continued strong international revenue growth, maintaining or exceeding Q1's growth rate. Clear progress toward international segment profitability. | Company earnings calls and releases (next expected Q2 2026 earnings on August 10, 2026). Investor presentations. | Google Trends: Search interest for Hims/Hers/ZAVA/Livewell in the U.K., Germany, Canada, Australia. | Similarweb: Web traffic for international Hims & Hers domains (e.g., forhims.co.uk, forhers.de). |
| Branded GLP-1 Product Adoption & Weight Loss Subscriber Growth | This factor indicates the success of Hims & Hers' strategic pivot to branded GLP-1s, expanding its addressable market, driving significant subscriber growth, and de-risking previous concerns about compounded GLP-1 regulatory exposure. | Sustained addition of new weight loss subscribers per month (target: >100,000). Total shipments of branded GLP-1 products (e.g., Wegovy, Zepbound). Subscriber engagement metrics like app downloads (~90% in Q1 2026) and provider interactions (average 3 times in the first month for new subscribers). | Bullish: Continued addition of >100,000 new weight loss subscribers per month. Consistent high engagement metrics for branded GLP-1 users. | Company earnings calls and releases (next expected Q2 2026 earnings on August 10, 2026). Investor presentations. | Google Trends: 'Wegovy pill Hims', 'Zepbound Hims' search volume. Reddit/social media sentiment analysis for Hims & Hers weight loss offerings. | Similarweb: Hims.com web traffic, conversion rates for weight loss pages. Sensor Tower: Hims & Hers app download and engagement data. |
| Labs, Menopause, and Low-T Specialties Scale & AI Integration | The successful scaling of these newer specialties, combined with advanced AI integration, demonstrates the platform's ability to diversify beyond core offerings, drive proactive care, and enhance customer engagement and retention, supporting higher LTV. | Progression of Labs, menopause, and low-T specialties toward a $100M+ run rate each. Labs engagement metrics (e.g., conversion to treatment plans >70%). Updates on AI agent rollouts (Labs AI, AI weight loss companion) and their impact on efficiency/quality. | Bullish: Continued strong growth in these specialties, meeting or exceeding conversion targets. Positive feedback/metrics on AI tool effectiveness and adoption. | Company earnings calls and releases (next expected Q2 2026 earnings on August 10, 2026). Investor presentations. | Google Trends: 'Hims testosterone', 'Hers menopause', 'Hims Labs' search volume. App store reviews for Hims & Hers app mentioning AI features. | Thinknum: Job postings for AI/ML engineers at Hims & Hers (growth indicates investment). Sensor Tower: App feature usage data. |
Key Reported Metrics, Reratings Triggers & ResultsThis metric will show the immediate impact of strategic investments and the weight loss pivot on profitability. Investors will watch for signs of margin compres
| Key reported metrics | Rerating thresholds | Earnings results | ||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Last period | Why it matters | What's needed for rerating | Rerating context | Earnings date | Actual reported | Hit target? | Notes |
| Adjusted EBITDA Margin | 7% | This metric will show the immediate impact of strategic investments and the weight loss pivot on profitability. Investors will watch for signs of margin compression and progress towards the anticipated H2 improvement in EBITDA dollars. | HIMS needs to deliver an Adjusted EBITDA margin of 12% or higher for the quarter, significantly beating its 10% guidance. Additionally, the company must maintain YoY EBITDA growth above 150% (relative to the current 315% baseline). Crucially, management must provide FY 2026 Adjusted EBITDA guidance in the $260M–$280M range, signaling a return to a 13-15% margin profile. | Hitting this threshold proves HIMS' business model sustainability amidst GLP-1 pricing pressure and regulatory uncertainty. It confirms verticalization provides a structural cost advantage, enabling margin expansion while underpricing competitors. This de-risks the 'value trap' narrative and validates the path toward their $1.3B 2030 EBITDA target. | ||||
| Total Revenue | 4% | Total Revenue is the primary indicator of the platform's overall scale and growth. Management raised the full-year guidance, making Q2 performance crucial for validating the acceleration post-strategic pivot in the weight loss business. | HIMS needs to deliver Q2 2026 revenue significantly exceeding its guidance of $680 million to $700 million, ideally demonstrating year-over-year growth approaching or surpassing 40%. Additionally, the company should raise its full-year 2026 revenue guidance above the current $2.8 billion to $3.0 billion range, further validating the acceleration of its strategic pivot. | Hitting this threshold would validate HIMS's strategic pivot to branded GLP-1s and new specialties, demonstrating sustainable volume growth and diversifying revenue beyond compounding risks. This would restore investor confidence in its transition to a durable, high-growth proactive health platform, justifying a higher valuation. | ||||
| International Revenue | 900% | This segment is a key growth engine, demonstrating the success of global expansion efforts and the impact of acquisitions like ZAVA and Livewell, with the planned Eucalyptus acquisition expected to close in 2H 2026. | International Revenue growth needs to maintain or exceed Q1 2026's year-over-year growth rate of 900%, and the company must demonstrate clear progress toward international segment profitability. | Achieving this validates HIMS's global expansion strategy and the effectiveness of acquisitions like Eucalyptus. It demonstrates successful revenue diversification, expands the addressable market, and mitigates concerns about margin compression, reinforcing the thesis of HIMS as a growing, consumer-centric health ecosystem. | ||||
Key QuestionsWill Hims & Hers meet its Q2 2026 revenue and adjusted EBITDA guidance, demonstrating the anticipated acceleration and margin improvement following the strategi
Will Hims & Hers meet its Q2 2026 revenue and adjusted EBITDA guidance, demonstrating the anticipated acceleration and margin improvement following the strategic pivot to branded GLP-1s?
- Question 2
Will the FDA provide clear regulatory guidance on peptide therapies in July 2026, and can Hims & Hers demonstrate its readiness to launch these offerings with its 'best in market' approach, leveraging its verticalized supply chain?
- Question 3
Will the planned acquisition of Eucalyptus close in the second half of 2026 as expected, and will Hims & Hers show progress towards its international break-even timeline and accelerated revenue contribution from global expansion?
Earnings Transcript Summary
· 2026Q1 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. Accelerating growth and market leadership: Management is focused on expanding the U.S. business with new specialties like weight loss (pivoting to branded GLP-1s), testosterone, menopause, and labs, alongside aggressive international expansion, notably through the planned acquisition of Eucalyptus. 2. Leveraging data and AI for enhanced customer experience and care quality: The company is building a smarter, more agile platform by integrating AI agents, such as the Labs AI health care agent, an AI copilot for providers, and an upcoming AI weight loss companion, to personalize care, improve outcomes, and deepen customer relationships. 3. Strategic investments in verticalized infrastructure and technology: Hims & Hers is investing in facilities to expand capabilities and operating efficiency, including at-home blood collection technology (YourBio) and a U.S.-based peptide facility, to support new offerings, reduce costs, and ensure high safety and quality standards. | The call conveyed that Hims & Hers is undergoing a significant strategic transition, particularly in its weight loss business by pivoting to branded GLP-1s, and is aggressively investing in new specialties (labs, testosterone, menopause, peptides) and international expansion. Management acknowledged that these investments and strategic shifts would create near-term GAAP financial volatility and margin pressure. However, the overall tone was confident and ambitious, emphasizing accelerating growth, leveraging AI and verticalized infrastructure, and a strong conviction in achieving its ambitious 2030 targets. | Total Revenue: 28% year-over-year. International Revenue: 825% year-over-year. U.S. Operations Revenue: Not explicitly stated as a percentage for Q4 2025. | 1. Weight Loss Strategic Pivot (Branded vs. Compounded GLP-1s) and its Financial Impact: Analysts questioned the economics of branded versus compounded products, the subscriber transition, and the pivot's effect on guidance. Management responded that branded and compounded products are roughly comparable on a dollar basis, the pivot significantly expands the addressable market, and early success signals (over 100,000 new weight loss subscribers per month) reinforced the decision to elevate the guide. 2. Peptides Opportunity and Readiness: Analysts inquired about the company's long-term peptide strategy, potential differentiation, competitive advantages from its domestic supply chain, and readiness for market entry. Management emphasized a strategy of being 'best in market' rather than 'first to market,' focusing on physician oversight, a safe and verticalized U.S. supply chain, and rigorous clinical protocols, noting the instinctively large demand driven by proactive health trends. 3. Gross Margin Compression and H2 EBITDA Ramp: Analysts pressed on the expected degradation in gross margins and the confidence in achieving higher incremental EBITDA margins in the second half of the year. Management explained that gross margins are expected to compress by a couple of points in coming quarters due to the strategic pivot and scaling lower-margin specialties (weight loss, labs, international). They expressed high conviction in the H2 EBITDA ramp, attributing it to the compounding effect of monthly cohorts from shorter shipping cadences, operating leverage in G&A, and continued marketing efficiency gains. | Total Revenue: 4% year-over-year to $608 million. International Revenue: Nearly tenfold (900%) year-over-year to $78 million. U.S. Operations Revenue: Temporarily pressured (no specific percentage given). |
· 2025Q4 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1) Diagnostics and devices innovation to expand the health platform (Labs, YourBio, wearables integration). 2) AI as a critical layer to personalize care and scale operations (data, AI tools, proactive messaging). 3) Deeper data and more proactive, personalized treatments, plus international expansion and category diversification to reach 2030 targets. | The call framed Hims & Hers as aggressively evolving into a global, consumer-centric proactive health platform. Near-term margin pressures and some revenue timing headwinds exist from shipping cadence changes and category transitions, but management conveyed confidence in leveraging a strong balance sheet and strategic investments to drive long-term growth and a path to 2030 targets. Tone: confident and ambitious. | Hims US: >40% YoY in Q3 2025; Hers US: triple-digit YoY in Q3 2025; International: not disclosed in Q3 2025 transcript. | 1) GLP-1 regulatory risk and potential branded Wegovy partnership with Novo Nordisk; mgmt response: pursuing branded Wegovy alongside compounded options and leveraging verticalization to lower prices while aiming to preserve long-term margins. 2) Margin expansion pause due to investments in technology and infrastructure; mgmt response: these investments are high-ROI and expected to drive future growth and free cash flow. 3) Durability of growth and mix shift away from GLP-1 toward Labs, menopause, low testosterone and other offerings; mgmt response: diversification strategy supported by labs/menopause/low-T and international expansion to sustain growth and LTV. | U.S. Hims revenue growth: over 30% YoY in 2025; U.S. Hers revenue growth: triple-digit YoY in 2025; International revenue growth: almost 400% YoY in 2025 to $134 million. |
· 2025Q3 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. Verticalization and Infrastructure: Expanding facility footprint to over 1 million square feet to support internal 503A sterile compounding, which management believes establishes a 'gold standard' for safety and allows for price reductions in GLP-1 and testosterone treatments. 2. Proactive Health and Diagnostics: Launching whole-body lab testing by year-end 2025 and a Longevity specialty in 2026 to shift the platform from reactive treatment of conditions to proactive health management. 3. Global Scale: Integrating the Zava acquisition to reach 200 million adults in Europe and preparing for a Canada launch in 2026, targeting a $1 billion+ international revenue opportunity. | The takeaway is that Hims & Hers is aggressively evolving from a telehealth provider for specific conditions into a vertically integrated, global 'proactive health' platform. While the company is facing near-term margin pressure and revenue headwinds from shipping cadence changes and segment transitions, management is 'leaning in' to its $1.1 billion cash position to fund massive expansion in diagnostics and longevity. The tone was extremely confident and ambitious, characterized by a 'build the future' mentality. | In Q2 2025, Total Revenue grew 52% y/y (indicating a slight deceleration to 49% in Q3). Subscriber growth in Q2 2025 was 43% y/y (decelerating to 20% y/y in Q3, though management highlighted specific segment strengths). | 1. GLP-1 Strategy and Novo Nordisk Partnership: Analysts questioned the impact of price cuts and the status of discussions with Novo Nordisk. Management responded that they are in active discussions to offer branded Wegovy alongside compounded options and that verticalization allows them to lower prices while maintaining long-term margin targets. 2. Margin Compression and Investment: Analysts pressed on the 'temporary pause' in margin expansion due to increased spending. Management explained that heavy investments in tech talent, AI-assisted tools, and infrastructure are high-ROI initiatives that will drive the next phase of growth and long-term free cash flow. 3. Core Business Growth Deceleration: Analysts asked about slowing growth in legacy segments like sexual health. Management responded that they are intentionally transitioning users from generic on-demand solutions to personalized daily treatments, which creates a short-term headwind but will lead to more durable recurring growth and acceleration in H2 2026. | Total Revenue: 49% y/y growth; Hers Brand: Near or above triple-digit y/y growth; Hims Brand (Subscribers): >40% y/y growth when excluding the sexual health transition impact; Weight Loss Specialty: On track for >$725M in 2025 revenue. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| The U.S. business is positioned to accelerate with the introduction of new specialties like testosterone, menopause, and labs. The expanding selection of branded GLP-1 solutions is driving accelerating momentum in the weight loss business, with over 100 million adults in the U.S. struggling with weight. Within weeks of introducing direct access to Novo Nordisk GLP-1 products, the platform fulfilled over 125,000 shipments for Wegovy. Providers can now also send prescriptions for Zepbound to LillyDirect pharmacy. The planned acquisition of Eucalyptus in the second half of this year will extend leadership across Australia, the U.K., Germany, Japan, and Canada, with the opportunity to impact hundreds of millions of people. The introduction of branded weight loss products is expanding the addressable market significantly, with the company on track to add over 100,000 new subscribers per month in the weight loss specialty. New categories like labs, menopause, and testosterone are iterating domestically before expanding to other geographic regions within 6 to 9 months. | Global scale is quickly becoming a competitive advantage, expanding TAM and value to industry partners, strengthening network effects. The company is deepening customer relationships by filling gaps in traditional care with proactive offerings. Continued investment in data and technology infrastructure is building an agile platform that gets smarter with every new customer, creating a powerful, hard-to-replicate data set. The platform is becoming a go-to for pharma, biotech, and diagnostic companies to reach more people. Hims & Hers is rapidly becoming the world's largest consumer health platform and sees itself as the best global platform for industry partners due to global presence and personalized experience. The closed-loop proprietary data flywheel is difficult for competitors to recreate, as it's one of the only platforms where consumer intake, diagnosis, treatment, provider decisions, and outcomes live in a single stack. The integration of providers, portables, and regulatory infrastructure creates a unified care model that sets it apart from traditional LLMs or frontier AI labs. The verticalized infrastructure and domestic supply chain, including a U.S.-based peptide facility, provide advantages in quality, purity, reliability, and brand trust that will be difficult for others to match. | The weight loss market is evolving rapidly with more form factors and lower prices. Platforms like Hims & Hers are increasingly relied upon by pharma, biotech, and diagnostic companies to reach more people with innovative treatments and services. More customers are seeking proactive and continuous care, informed by health insights, to not just get healthy but stay healthy. In the emerging peptide category, the standard bearers will be companies prioritizing physician-first, transparent experiences focused on successful customer outcomes, contrasting with the current unregulated, inconsistent gray market. There is a growing emergence, likely provoked by the GLP-1 category, of patients seeking to be more proactive with health, focusing on preventative and longevity-focused care rather than just acute issues. | 2026 is a year of accelerating growth, reinforcing confidence in ambitious 2030 targets. Hims & Hers aims to become an everyday health partner for millions more globally. The planned acquisition of Eucalyptus is expected to close in the second half of this year. The company will continue investing in technology in the near term, expecting benefits to cascade across the platform. Investments in talent will support expansion into complex offerings like injectable low testosterone treatments and new offerings like peptides as the regulatory landscape evolves. The company expects to return to net income profitability in 2027. For the full year 2026, revenue outlook is raised to $2.8 billion to $3 billion, with adjusted EBITDA expected between $275 million and $350 million. Gross margins are expected to compress as the company prioritizes scaling weight loss, labs, and international markets. A meaningful step-up in adjusted EBITDA dollars is anticipated in the third and fourth quarters. Technology investments are expected to yield efficiency benefits starting in 2027. The company is confident in replicating its success and establishing category leadership in international markets like Canada, the U.K., Australia, and other European countries, maintaining 2030 ambitions of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA. | Peptide | Proactive Longevity & Diagnostics: There is a growing trend of patients seeking to be more proactive with their health, focusing on preventative and longevity-focused care, rather than solely addressing acute issues. This is evident in the demand for emerging therapies like peptides and the growth of categories such as lab testing, testosterone, and menopause, where individuals are taking more control of their health. | 2026 has proven to be a year of accelerating growth. Our U.S. business is positioned to accelerate as we introduce new specialties. Our global scale is quickly becoming a competitive advantage. Within weeks of this launch, we are on track to add north of 100,000 new subscribers per month within our weight loss specialty. We are rapidly becoming the world's largest consumer health platform. I have never been more confident that we are building the future of health. For the full year, we are raising our 2026 revenue outlook to $2.8 billion to $3 billion. | In the first quarter, revenue grew 4% year-over-year to $608 million. Adjusted EBITDA was $44 million, representing a 7% adjusted EBITDA margin. We incurred approximately $33 million of restructuring costs, primarily consisting of the write-downs related to our compounded GLP-1 supply chain that now face risk of obsolescence. Approximately $28 million of onetime charges negatively impacted gross margins by roughly 5 points in the first quarter. GAAP net income declined to a loss of $92 million in Q1. We expect gross margins to compress as we prioritize scaling areas such as weight loss, labs and international markets. Near-term margin headwinds are expected in the second quarter as the majority of our weight loss specialty moves toward 1-month shipments. | The engineering team is lean and talented, driven by senior leaders. The AI organization has been built from scratch and now includes nearly 40 members, comprising senior AI engineers, applied scientists (PhDs from MIT, Berkeley), and seasoned leaders from top tech companies. The company expects to continue investing in talent and capabilities across technology and operations. Specifically, talent investments were made in Q1 to expand into more complex offerings like injectable low testosterone treatments and to prepare for new offerings such as peptides as the regulatory landscape evolves. AI is expected to reduce organizational and operational costs, enhancing service quality and meaningfully reducing the cost to serve consumers, with some efficiency benefits potentially emerging in 2027. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Expanding TAM via new specialties (low testosterone, menopause, Labs) and rapid geographic expansion (Canada; U.K., Germany, France, Ireland, Spain; Australia and Japan via Eucalyptus; ZAVA and Livewell acquisitions) with 2.5M+ subscribers; 130+ biomarkers; aim for >$1B incremental international revenue in 3 years. | Scalability and vertical integration as a moat; price reductions on GLP-1 to improve access and margins; active discussions with Novo Nordisk to offer branded Wegovy on the platform; potential regulatory scrutiny of GLP-1 compounding; competition from traditional providers as the platform expands into diagnostics and longevity. | Industry shifting from reactive treatment to proactive, preventative care; diagnostics and wearables integration; AI as a critical layer; mass-market at-home testing and data-driven personalization are becoming core to health platforms. | Long-term targets include $6.5B revenue and $1.3B adjusted EBITDA by 2030; international business expected to break even within 12–18 months after Eucalyptus closing; 2026 guidance for revenue and EBITDA; labs, testosterone, menopause and AI-enabled platform experiences to scale with ongoing international expansion. | Premium | Proactive Longevity & Diagnostics: broad shift to accessible, mass-market health diagnostics and proactive care across life stages. | "The opportunity is significant."; "Hers brand is on pace to deliver revenue of over $1 billion in 2026."; "Active discussions with Novo Nordisk to make Wegovy injections available through our platform."; "In just 90 days, we created 3 distinct new entry points to our platform." | "Gross margins declined approximately 2 points quarter-over-quarter to 72%."; "Headwinds in the fourth quarter from shorter shipment cadences."; "Approximately $65 million revenue headwind in Q1 2026 from shipping cadences in weight loss." | Investments in technology and AI talent, safety/compliance staffing, and leadership hires; international headcount growth and expansion of facilities to over 1 million square feet; notable marketing spend such as the 60-second Super Bowl ad as part of brand education. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Hims & Hers is aggressively expanding its TAM through new specialties including low testosterone, perimenopause, and menopause. The company is launching comprehensive whole-body lab testing before year-end 2025 and a longevity specialty in 2026. Geographically, they are expanding into Canada (targeting 2/3 of adults who are overweight) and leveraging the Zava acquisition to reach 200 million adults across the U.K., Germany, France, Ireland, and Spain. They are also in active discussions with Novo Nordisk to offer Wegovy and oral semaglutide. | The company views its scale as a primary competitive advantage, allowing it to act as a 'powerful curator' of health solutions. They are positioning themselves against traditional providers by offering personalized, high-touch care that is often stigmatized or hard to access. To maintain a leadership position in weight loss, they strategically reduced compounded GLP-1 prices by up to 20%. They are also preparing for the 2026 entry of generic semaglutide by engaging with leading generic manufacturers. | The industry is shifting from reactive treatment of existing conditions to proactive, preventative health management. There is a significant gap in specialized care, noted by the fact that only 30% of OB/GYN residency programs offer formal training on menopause. The company also highlights a 'green list' of FDA-registered GLP-1 API suppliers, signaling a tightening of regulatory and quality standards in the compounding space. | HIMS is tracking toward its 2030 goal of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA. The Hers brand is expected to reach $1 billion in annual revenue by 2026. The company is transitioning its sexual health business from on-demand generics to daily personalized treatments, a shift expected to normalize by late 2026. Future growth will be driven by 'verticalizing' sterile compounding infrastructure and integrating AI-assisted tools like nutritional coaches. | Premium | Proactive Longevity & Diagnostics: A shift toward 'the great equalization' of high-end diagnostics, moving from $5,000+ boutique testing to affordable, mass-market whole-body screening for early detection of cancer and cardiovascular disease. | "Subscribers using personalized solutions grew 50% year-over-year."; "Hers brand... on pace to deliver revenue of over $1 billion in 2026."; "Active discussions with Novo Nordisk to make Wegovy injections... available through our platform."; "Marketing as a percentage of revenue was 39%, representing more than 6 points of leverage." | "Gross margins declined over 2 points quarter-over-quarter to 74%."; "Headwinds in the fourth quarter from shorter shipment cadences."; "Temporary pause in year-over-year margin expansion."; "Continued moderation in our on-demand sexual health business." |
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | Price Reaction |
|---|---|---|---|---|---|
| 2026-02-23 | Hims & Hers reported Q4 revenue of $618M (up 28% YoY) and full-year revenue of $2.35B, guiding 2026 revenue of $2.7-2.9B with adjusted EBITDA of $300-375M. Growth drivers include Labs, menopause, low-T and faster international expansion. The market reacted modestly negative: stock -0.32% on earnings day, underperforming SPY, suggesting skepticism about GLP-1 exposure and near-term margins despite a clear long-term platform pivot to proactive care and 2030 targets. | Other | Neutral | https://investors.hims.com/news-releases/news-release-details/hims-hers-health-reports-fourth-quarter-and-full-year-2025-earnings | -0.32% (vs SPY: -1.05%) |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| HIMS_9e266949 | end of July | 2026-07-27 | 2026-07-31 | The FDA is expected to provide more clarity on the reclassification of certain peptide therapies, potentially moving some to Category One. | This regulatory clarity is crucial for Hims & Hers to proceed with its plans to enter the peptide therapy category with a clinically rigorous and safe approach, potentially unlocking a new and large market opportunity. | Theme | 2026-05-11 | earnings_transcript |
| HIMS_8ce0db05 | within 12 to 18 months | 2027-02-23 | 2027-08-23 | Management target for the collective international business (inclusive of Eucalyptus) to reach break-even on an adjusted EBITDA basis within 12–18 months. | Achievement would validate international scaling playbook, reduce consolidated margin drag and accelerate path to 2030 EBITDA targets; failure to reach break-even would prolong international margin pressure and may require additional investment or slower expansion. | Ticker | 2026-02-23 | earnings_transcript |
| HIMS_1e455609 | second half of this year | 2026-07-01 | 2026-12-31 | Signed acquisition of Eucalyptus — closing of the Eucalyptus transaction. | Closing materially expands Hims & Hers' international footprint (UK/Europe, Australia, Japan), requires upfront ~ $240M cash at close and up to $1.15B total consideration, and could materially change 2026 revenue mix, cash use, and near-term adjusted EBITDA given integration costs and expected revenue contributions. | Ticker | 2026-02-23 | earnings_transcript |
| HIMS_27d621bf | second half of this year | 2026-07-01 | 2026-12-31 | Management expectation that Eucalyptus will contribute at least $200 million of incremental revenue in H2 2026 upon closing. | If realized, this would meaningfully boost 2H26 and full-year international revenue, alter guidance realization and investor perception; failure to realize these contributions (due to delayed close or weaker performance) would weaken FY26 revenue and international growth assumptions. | Ticker | 2026-02-23 | earnings_transcript |
| HIMS_7a775872 | in 2026 | 2026-01-01 | 2026-12-31 | Integration and scaling of YourBio's microneedle at‑home blood-sampling technology into Hims & Hers' Labs offering (post-close integration to enable at‑home diagnostics). | Successful integration could accelerate Labs adoption, increase addressable market and data-driven personalization (raising LTV and cross-sell), while delays or poor execution would slow diagnostic-led growth and reduce anticipated unit-economics improvements. | Ticker | 2026-02-23 | earnings_transcript |
| HIMS_b020aa58 | next few years | 2026-02-23 | 2028-02-23 | Ongoing regulatory and legal scrutiny of compounded GLP-1s (FDA/DOJ engagement and potential restrictions or changes to compounding policy, including removal from shortage lists or bans on certain compounded semaglutide products). | A regulatory restriction or ban on compounded GLP-1s would remove a high-ticket, fast-growing revenue stream and could materially compress revenue and adjusted EBITDA; conversely, a favorable regulatory outcome or secured branded supply partnerships would de-risk weight-loss revenue and support guidance — the outcome affects demand, pricing, and supply strategy. | Theme | 2026-02-23 | earnings_transcript |